openPR Logo
Press release

Global Renovascular Hypertension Treatment Market Size, Share, and Growth Opportunities till 2028 by Fact.MR || Top Key Players- Novartis AG; Merck & Company, Inc.; AstraZeneca plc.; Johnson and Johnson; Eli Lilly

09-17-2018 11:37 AM CET | Health & Medicine

Press release from: Fact.MR

Fact.MR

Fact.MR

A fresh study, covering “Renovascular Hypertension Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2018 to 2028” has been broadcasted to wide online repository of FactMR, which presents deep focus on the Renovascular Hypertension Treatment Market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make the research a powerful source for analysts and industry experts who are looking to gain necessary knowledge about the prevailing market trends, opportunities and drivers present in the Renovascular Hypertension Treatment Market. 

Request For Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=1725

Renovascular hypertension can be defined as high blood pressure caused by renal artery diseases mainly due to the narrowing of the renal artery. Renal artery diseases, such as renal artery stenosis, result in reduced blood flow due to the narrowing of the artery that provides blood to the kidney. When the kidney receives low blood flow, it responds by releasing hormones that stimulate the body to retain sodium and water as the blood pressure goes up. Major causes of renovascular hypertension are renal artery stenosis, atherosclerosis and fibromuscular dysplasia. Renovascular hypertension is hard to diagnose and generally has no signs or symptoms. Renal hypertension can cause chronic kidney disease. At the beginning of renovascular hypertension treatment, medications are given to control high blood pressure. Antihypertensive drug therapy is given for renovascular hypertension treatment.  Blood pressure regulator medication, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and diuretic drugs, are the primary drugs used for renovascular hypertension treatment. Sometimes, calcium channel blocker, beta blockers and other blood pressure medications are also prescribed for renovascular hypertension treatment if required. Angiotensin-Converting Enzyme (ACE) inhibitors given for renovascular hypertension treatment interrupt the conversion of angiotensin I and angiotensin II. Benazepril, captopril, lisinopril, ramipril, enalapril and captopril are the common ACE inhibitors used for renovascular hypertension treatment. Common angiotensin II receptor blockers for renovascular hypertension treatment include candesartan, losartan, valsartan and olmesartan.

Renovascular Hypertension Treatment Market: Drivers and Restraints

The growing prevalence of kidney disorders is expected to be a major factor driving the growth of the renovascular hypertension treatment market over the forecast period. Renovascular hypertension is the main cause of chronic kidney disorder. According to the National Institute of Diabetes and Kidney Diseases, more than 661,000 Americans suffer from kidney failure and in 2013, more than 47,000 Americans died of kidney disease. Private and public healthcare organisations are increasingly undertaking initiatives for the management of kidney diseases, which is expected to spur the growth of the renovascular hypertension treatment market. National Institute of Diabetes and Kidney Diseases (NIDDK), National Institutes of Health (NIH) and CDC conduct screening programs and support research related to several diseases and conditions. The renovascular hypertension treatment market is expected to register a high growth rate due to an increase in the number of clinical trials for drug development with the support of government organisations. Unhealthy lifestyle, stress, obesity, increase in smoking and the high prevalence of diabetes & cholesterols are also among factors expected to boost the renovascular hypertension treatment market.  Increase in the prevalence of primary renal diseases, such as renal artery stenosis, atherosclerosis and focal segmental glomerulosclerosis is also a major driving factor driving the renovascular hypertension treatment market. However, lack of awareness regarding renovascular hypertension due the absence of symptoms is expected to restrain the renovascular hypertension treatment market.

To know more about the Renovascular Hypertension Treatment Market Trends, visit this link- https://www.factmr.com/report/1725/renovascular-hypertension-treatment-market

Renovascular Hypertension Treatment Market: Overview

The global market for renovascular hypertension treatment is expected to witness moderate growth over the forecast period. Angiotensin-Converting Enzyme (ACE) inhibitor is expected to contribute a major revenue share in the renovascular hypertension treatment market. In addition, with ACE inhibitors or angiotensin II receptor blockers, diuretic drugs are prescribed to helps the kidney remove fluid from the blood. The retail pharmacy distribution channel is expected to contribute a high share in the global renovascular hypertension treatment market as it is the most accessible channel and the majority of patients are recommended for outpatient treatment.

Renovascular Hypertension Treatment Market: Regional Outlook

Geographically, the global renovascular hypertension treatment market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). North America is expected to be the dominant market in the global renovascular hypertension treatment market owing to highly supportive government initiatives. Europe is expected to have the second-largest share in the global renovascular hypertension treatment market throughout the forecast period owing to the growing awareness related to major health issues. The renovascular hypertension treatment market in the Asia Pacific excluding Japan region is expected to grow at a significant CAGR due to an increase in healthcare expenditure and growth in the number of healthcare facilities. 

Renovascular Hypertension Treatment Market: Key Players

Examples of some of the key players operating in the global renovascular hypertension treatment market are Abbott Laboratories; Pfizer Inc.; Novartis AG; Merck & Company, Inc.; AstraZeneca plc.; Johnson and Johnson; Eli Lilly and Company; Sanofi SA; Bayer AG; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd. and others. Companies are conducting clinical trials for the development of new renovascular hypertension treatment drugs, which is expected to boost the growth opportunities of the renovascular hypertension treatment market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Have Any Query? Discuss with Our Expert Team- https://www.factmr.com/connectus/sample?flag=AE&rep_id=1725

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Renovascular Hypertension Treatment Market Size, Share, and Growth Opportunities till 2028 by Fact.MR || Top Key Players- Novartis AG; Merck & Company, Inc.; AstraZeneca plc.; Johnson and Johnson; Eli Lilly here

News-ID: 1241997 • Views:

More Releases from Fact.MR

Non-Alcoholic Wine Market to Expand at 10% CAGR, Reaching $5.2 Billion by 2033
04-19-2024 | Food & Beverage
Fact.MR
Non-Alcoholic Wine Market to Expand at 10% CAGR, Reaching $5.2 Billion by 2033
The global demand for non-alcoholic wine is predicted to grow at a 10% CAGR between 2023 and 2033. The global non-alcoholic wine market is currently valued at $2 billion and is expected to grow to $5.2 billion by 2033. Increased demand for nonalcoholic wine in Middle Eastern nations like Kuwait and the UAE will drive market expansion. Athletes and pregnant women are the primary consumers of non-alcoholic wine. The health ramifications
Personal Floatation Devices Market Soars, Expected to Hit US$ 8,014 Million by 2032
04-19-2024 | Sports
Fact.MR
Personal Floatation Devices Market Soars, Expected to Hit US$ 8,014 Million by 2 …
The global personal floatation devices market is expected to be valued at US$ 3,178.7 million in 2022, growing at a CAGR of 9.7% to US$ 8,014 million by the end of 2032. The personal flotation device market is transitioning from 'distributor-based' sales to direct-to-customer online channels. Catering to the needs of last-mile consumers is a profitable opportunity for manufacturers, and utilising online sales channels can help businesses capitalise on the emerging
Paper Bottle Market Expected to Expand at 6.2% CAGR by 2033
Paper Bottle Market Expected to Expand at 6.2% CAGR by 2033
The Paper Bottles Market is estimated to reach US $ 53.31 million by 2033, with a 6.2% growth rate during the forecast period. Paper bottle sales are fast increasing, owing to both the growing need for alternatives to plastic bottles and the degradability and eco-friendliness of these containers. Paper bottle sales are expected to rise as demand for beverages rises and effective storage becomes more important. Get Free Sample Copy of This
Halloumi Cheese Market Surges Past US$ 1.2 Billion Mark by 2033, Fueled by 10.4% CAGR
04-19-2024 | Food & Beverage
Fact.MR
Halloumi Cheese Market Surges Past US$ 1.2 Billion Mark by 2033, Fueled by 10.4% …
It is anticipated that halloumi cheese market will be valued at US$ 445 million in 2023 and surpass US$ 1.2 billion by the end of 2033. It is projected that the worldwide market for halloumi cheese will grow at an astounding rate of 10.4% CAGR till 2033. Cyprus, a Middle Eastern nation, is the birthplace of halloumi cheese, which has been made there by local farmers for generations. Since this nation

All 5 Releases


More Releases for Renovascular

07-21-2021 | Health & Medicine
Fact.MR
Growing Prevalence Of Kidney Disorders Is Expected To Drive Demand Of Renovascul …
The Recent study by Fact.MR- (leading business and competitive intelligence provider) On global Renovascular Hypertension Treatment market Survey study presents an all in all compilation of the historical, current and future outlook of Renovascular Hypertension Treatment market as well as the factors responsible for such a Renovascular Hypertension Treatment Market growth. The report on the market survey of Renovascular Hypertension Treatment gives estimations of the Size of Renovascular Hypertension Treatment Market
06-28-2019 | Health & Medicine
Fact.MR
Atherosclerotic Renovascular Treatment Market Regional Growth Trends Focusing on …
Atherosclerotic renovascular disease refers to the stenosis of either one or both renal arteries. The stenosis occurs due to the accumulation of fat or calcium deposits on the walls of the artery. Atherosclerotic renovascular disease is a rare disorder and its exact epidemiology is not available. Although the prevalence of atherosclerotic renovascular disease is not known, the dialysis registry data provides some hint of patients with atherosclerotic renovascular disease. In
Atherosclerotic Renovascular Treatment Market Soaring Demand Assures Motivated R …
Atherosclerotic renovascular disease refers to the stenosis of either one or both renal arteries. The stenosis occurs due to the accumulation of fat or calcium deposits on the walls of the artery. Atherosclerotic renovascular disease is a rare disorder and its exact epidemiology is not available. Although the prevalence of atherosclerotic renovascular disease is not known, the dialysis registry data provides some hint of patients with atherosclerotic renovascular disease. In
Global Atherosclerotic Renovascular Treatment Market Insights, Trends & Future D …
A fresh study, covering “Global Atherosclerotic Renovascular Treatment Market Insights, Trends & Future Development Status Recorded during 2018-2028” has been broadcasted to wide online repository of FactMR, which presents deep focus on the Atherosclerotic Renovascular Treatment Market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
Atherosclerotic Renovascular Treatment Market Comprehensive Analysis of World Ma …
Atherosclerotic renovascular disease refers to the stenosis of either one or both renal arteries. The stenosis occurs due to the accumulation of fat or calcium deposits on the walls of the artery. Atherosclerotic renovascular disease is a rare disorder and its exact epidemiology is not available. Although the prevalence of atherosclerotic renovascular disease is not known, the dialysis registry data provides some hint of patients with atherosclerotic renovascular disease. In
Renovascular Hypertension Treatment Market Analysis and Value Forecast Snapshot …
Renovascular hypertension can be defined as high blood pressure caused by renal artery diseases mainly due to the narrowing of the renal artery. Renal artery diseases, such as renal artery stenosis, result in reduced blood flow due to the narrowing of the artery that provides blood to the kidney. When the kidney receives low blood flow, it responds by releasing hormones that stimulate the body to retain sodium and water